Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Shorter hormone therapy for prostate cancer

EMUC 2019

14 - 17 Nov 2019

Published: 24 Feb 2020

Views: 989

Rating:

Save

Dr André-Guy Martin - Centre Hospitalier Universitaire de Québec, Québec City, Canada

Dr André-Guy Martin speaks to ecancer at EMUC 2019 in Vienna about an improved regimen of hormone therapy.

He outlines a recent study which showed little difference in overall survival if you used a long term hormone therapy regimen.

Dr Martin suggests a shorter regimen for those patients who do not tolerate the therapy particularly well.

Related Videos

Pegargiminase-pemetrexed-platinum triplet therapy prolongs survival in non...

Prof Peter Szlosarek - Barts Cancer Institute, London, UK

Pegargiminase-pemetrexed-platinum triplet therapy prolongs survival in non-epithelioid pleural mesothelioma ( Prof Peter Szlosarek - Barts Cancer Institute, London, UK )

Amivantamab shows robust efficacy in post-platinum therapy patients with EGFR...

Prof Nicolas Girard - Institut Curie, Paris, France

Amivantamab shows robust efficacy in post-platinum therapy patients with EGFR Ex20ins NSCLC ( Prof Nicolas Girard - Institut Curie, Paris, France )

Four chemo cycles given with durvalumab and tremelimumab optimise response and...

Dr Niels Reinmuth - University of Muenster, Gauting, Germany

Four chemo cycles given with durvalumab and tremelimumab optimise response and tumour shrinkage in patients with mNSCLC ( Dr Niels Reinmuth - University of Muenster, Gauting, Germany )

CodeBreaK 200 shows sotorasib to be a more tolerable treatment option for...

Dr David Waterhouse - Dana-Farber Cancer Institute, Boston, USA

CodeBreaK 200 shows sotorasib to be a more tolerable treatment option for patients with pretreated, KRASG12C-mutated advanced NSCLC ( Dr David Waterhouse - Dana-Farber Cancer Institute, Boston, USA )

Final data from phase II study of eftilagimod alpha and pembro in PD-1/PD-L1...

Dr Margarita Majem Tarruella - Hospital de la Santa Creu i Sant Pau, Barcelona...

Final data from phase II study of eftilagimod alpha and pembro in PD-1/PD-L1 inhibitors resistant second line metastatic NSCLC ( Dr Margarita Majem Tarruella - Hospital de la Santa Creu i Sant Pau, Barcelona, Spain )

Pembro monotherapy for participants with BCG–unresponsive HR NMIBC shows anti...

Prof Andrea Necchi - The Vita-Salute San Raffaele University, Milan, Italy

Pembro monotherapy for participants with BCG–unresponsive HR NMIBC shows anti-tumour activity ( Prof Andrea Necchi - The Vita-Salute San Raffaele University, Milan, Italy )

Intravesical IO using durvalumab shows promising results for patients with high...

Dr Charalampos Fragkoulis - General Hospital of Athens, Athens, Greece

Intravesical IO using durvalumab shows promising results for patients with high risk NMIBC after BCG failure ( Dr Charalampos Fragkoulis - General Hospital of Athens, Athens, Greece )

ASCO GU 2023: CRPC updates

Dr Neal Shore, Dr Elena Castro, Prof Gerhardt Attard and Prof Eleni Efstathiou

ASCO GU 2023: CRPC updates ( Dr Neal Shore, Dr Elena Castro, Prof Gerhardt Attard and Prof Eleni Efstathiou )

Final OS results of IMvigor130: Atezolizumab plus platinum/gemcitabine for mUC

Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA

Final OS results of IMvigor130: Atezolizumab plus platinum/gemcitabine for mUC ( Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA )

More from ecancer